Annual CFI
$12.22 M
-$100.45 M-89.16%
December 31, 2024
Summary
- As of March 10, 2025, FATE annual cash flow from investing activities is $12.22 million, with the most recent change of -$100.45 million (-89.16%) on December 31, 2024.
- During the last 3 years, FATE annual CFI has risen by +$336.24 million (+103.77%).
- FATE annual CFI is now -92.67% below its all-time high of $166.75 million, reached on December 31, 2022.
Performance
FATE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$22.82 M
-$2.65 M-10.39%
December 31, 2024
Summary
- As of March 10, 2025, FATE quarterly cash flow from investing activities is $22.82 million, with the most recent change of -$2.65 million (-10.39%) on December 31, 2024.
- Over the past year, FATE quarterly CFI has dropped by -$2.65 million (-10.39%).
- FATE quarterly CFI is now -71.61% below its all-time high of $80.38 million, reached on September 30, 2022.
Performance
FATE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$12.22 M
-$22.54 M-64.85%
December 31, 2024
Summary
- As of March 10, 2025, FATE TTM cash flow from investing activities is $12.22 million, with the most recent change of -$22.54 million (-64.85%) on December 31, 2024.
- Over the past year, FATE TTM CFI has dropped by -$22.54 million (-64.85%).
- FATE TTM CFI is now -93.39% below its all-time high of $184.92 million, reached on September 30, 2022.
Performance
FATE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
FATE Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -89.2% | -10.4% | -64.8% |
| 3 y3 years | +103.8% | -10.4% | -64.8% |
| 5 y5 years | +107.8% | -10.4% | -64.8% |
FATE Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -92.7% | +103.8% | -71.6% | +142.8% | -93.4% | +103.8% |
| 5 y | 5-year | -92.7% | +103.8% | -71.6% | +104.8% | -93.4% | +101.8% |
| alltime | all time | -92.7% | +103.8% | -71.6% | +104.8% | -93.4% | +101.8% |
Fate Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $12.22 M(-89.2%) | $22.82 M(-10.4%) | $12.22 M(-64.8%) |
| Sep 2024 | - | $25.46 M(-147.7%) | $34.76 M(+1.9%) |
| Jun 2024 | - | -$53.37 M(-408.3%) | $34.10 M(-71.7%) |
| Mar 2024 | - | $17.31 M(-61.8%) | $120.64 M(+7.1%) |
| Dec 2023 | $112.67 M(-32.4%) | $45.35 M(+82.8%) | $112.67 M(-6.4%) |
| Sep 2023 | - | $24.80 M(-25.2%) | $120.42 M(-31.6%) |
| Jun 2023 | - | $33.17 M(+255.1%) | $176.00 M(-3.9%) |
| Mar 2023 | - | $9.34 M(-82.4%) | $183.12 M(+9.8%) |
| Dec 2022 | $166.75 M(-151.5%) | $53.11 M(-33.9%) | $166.75 M(-9.8%) |
| Sep 2022 | - | $80.38 M(+99.5%) | $184.92 M(+1.3%) |
| Jun 2022 | - | $40.29 M(-673.4%) | $182.50 M(+29.6%) |
| Mar 2022 | - | -$7.03 M(-109.9%) | $140.84 M(-143.5%) |
| Dec 2021 | -$324.02 M(+101.2%) | $71.28 M(-8.6%) | -$324.02 M(-42.3%) |
| Sep 2021 | - | $77.96 M(-5782.1%) | -$561.33 M(-19.1%) |
| Jun 2021 | - | -$1.37 M(-99.7%) | -$693.43 M(+5.6%) |
| Mar 2021 | - | -$471.89 M(+184.2%) | -$656.74 M(+307.7%) |
| Dec 2020 | -$161.08 M(+2.3%) | -$166.03 M(+206.7%) | -$161.08 M(+52.6%) |
| Sep 2020 | - | -$54.14 M(-253.3%) | -$105.56 M(+597.4%) |
| Jun 2020 | - | $35.32 M(+48.6%) | -$15.14 M(-89.4%) |
| Mar 2020 | - | $23.77 M(-121.5%) | -$142.43 M(-9.5%) |
| Dec 2019 | -$157.45 M(>+9900.0%) | -$110.52 M(-404.6%) | -$157.45 M(+415.3%) |
| Sep 2019 | - | $36.29 M(-139.5%) | -$30.55 M(-43.0%) |
| Jun 2019 | - | -$91.98 M(-1150.7%) | -$53.56 M(-202.7%) |
| Mar 2019 | - | $8.75 M(-46.6%) | $52.13 M(<-9900.0%) |
| Dec 2018 | -$463.00 K | $16.38 M(+23.4%) | -$463.00 K(-87.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $13.28 M(-3.3%) | -$3.64 M(+11.0%) |
| Jun 2018 | - | $13.72 M(-131.3%) | -$3.28 M(-79.1%) |
| Mar 2018 | - | -$43.84 M(-432.1%) | -$15.66 M(+53.6%) |
| Dec 2017 | -$10.20 M(+147.8%) | $13.20 M(-3.2%) | -$10.20 M(-41.5%) |
| Sep 2017 | - | $13.64 M(+918.5%) | -$17.42 M(-43.1%) |
| Jun 2017 | - | $1.34 M(-103.5%) | -$30.60 M(+17.0%) |
| Mar 2017 | - | -$38.38 M(-742.0%) | -$26.15 M(+535.5%) |
| Dec 2016 | -$4.11 M(+174.6%) | $5.98 M(+1205.2%) | -$4.11 M(-59.9%) |
| Sep 2016 | - | $458.00 K(-92.1%) | -$10.27 M(-9.8%) |
| Jun 2016 | - | $5.79 M(-135.5%) | -$11.38 M(-34.5%) |
| Mar 2016 | - | -$16.34 M(+9082.0%) | -$17.39 M(+1060.9%) |
| Dec 2015 | -$1.50 M(+69.8%) | -$178.00 K(-72.8%) | -$1.50 M(-5.8%) |
| Sep 2015 | - | -$655.00 K(+207.5%) | -$1.59 M(+41.7%) |
| Jun 2015 | - | -$213.00 K(-52.9%) | -$1.12 M(+20.0%) |
| Mar 2015 | - | -$452.00 K(+66.8%) | -$936.00 K(+6.1%) |
| Dec 2014 | -$882.00 K(+270.6%) | -$271.00 K(+44.9%) | -$882.00 K(+15.9%) |
| Sep 2014 | - | -$187.00 K(+619.2%) | -$761.00 K(+28.8%) |
| Jun 2014 | - | -$26.00 K(-93.5%) | -$591.00 K(-6.0%) |
| Mar 2014 | - | -$398.00 K(+165.3%) | -$629.00 K(+164.3%) |
| Dec 2013 | -$238.00 K(-66.4%) | -$150.00 K(+782.4%) | -$238.00 K(+170.5%) |
| Sep 2013 | - | -$17.00 K(-73.4%) | -$88.00 K(+23.9%) |
| Jun 2013 | - | -$64.00 K(+814.3%) | -$71.00 K(+914.3%) |
| Mar 2013 | - | -$7000.00 | -$7000.00 |
| Dec 2012 | -$709.00 K(-454.5%) | - | - |
| Dec 2011 | $200.00 K | - | - |
FAQ
- What is Fate Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Fate Therapeutics?
- What is Fate Therapeutics annual CFI year-on-year change?
- What is Fate Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Fate Therapeutics?
- What is Fate Therapeutics quarterly CFI year-on-year change?
- What is Fate Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Fate Therapeutics?
- What is Fate Therapeutics TTM CFI year-on-year change?
What is Fate Therapeutics annual cash flow from investing activities?
The current annual CFI of FATE is $12.22 M
What is the all time high annual CFI for Fate Therapeutics?
Fate Therapeutics all-time high annual cash flow from investing activities is $166.75 M
What is Fate Therapeutics annual CFI year-on-year change?
Over the past year, FATE annual cash flow from investing activities has changed by -$100.45 M (-89.16%)
What is Fate Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of FATE is $22.82 M
What is the all time high quarterly CFI for Fate Therapeutics?
Fate Therapeutics all-time high quarterly cash flow from investing activities is $80.38 M
What is Fate Therapeutics quarterly CFI year-on-year change?
Over the past year, FATE quarterly cash flow from investing activities has changed by -$2.65 M (-10.39%)
What is Fate Therapeutics TTM cash flow from investing activities?
The current TTM CFI of FATE is $12.22 M
What is the all time high TTM CFI for Fate Therapeutics?
Fate Therapeutics all-time high TTM cash flow from investing activities is $184.92 M
What is Fate Therapeutics TTM CFI year-on-year change?
Over the past year, FATE TTM cash flow from investing activities has changed by -$22.54 M (-64.85%)